RESUMEN
Gout flares require monosodium urate (MSU) to activate the NLRP3 inflammasome and secrete sufficient IL-1ß. However, MSU alone is not sufficient to cause a flare. This is supported by the evidence that most patients with hyperuricemia do not develop gout throughout their lives. Recent studies have shown that, besides MSU, various purine metabolites, including adenosine triphosphate, adenosine diphosphate, and adenosine bind to different purine receptors for regulating IL-1ß secretion implicated in the pathogenesis of gout flares. Purine metabolites such as adenosine triphosphate mainly activate the NLRP3 inflammasome through P2X ion channel receptors, which stimulates IL-1ß secretion and induces gout flares, while some purine metabolites such as adenosine diphosphate and adenosine mainly act on the G protein-coupled receptors exerting pro-inflammatory or anti-inflammatory effects to regulate the onset and resolution of a gout flare. Given that the purine signaling pathway exerts different regulatory effects on inflammation and that, during the inflammatory process of a gout flare, an altered expression of purine metabolites and their receptors was observed in response to the changes in the internal environment. Thus, the purine signaling pathway is involved in regulating gout flare and resolution. This study was conducted to review and elucidate the role of various purine metabolites and purinergic receptors during the process.
Asunto(s)
Gota/etiología , Receptores Purinérgicos/fisiología , Adenosina Trifosfato/metabolismo , Antígenos CD/fisiología , Apirasa/fisiología , Gota/fisiopatología , Humanos , Proteína con Dominio Pirina 3 de la Familia NLR/fisiología , Receptores Purinérgicos/clasificación , Receptores Purinérgicos P2Y/fisiología , Transducción de Señal/fisiologíaRESUMEN
Purinergic G-protein-coupled receptors are ancient and the most abundant group of G-protein-coupled receptors (GPCRs). The wide distribution of purinergic receptors in the cardiovascular system, together with the expression of multiple receptor subtypes in endothelial cells (ECs) and other vascular cells demonstrates the physiological importance of the purinergic signaling system in the regulation of the cardiovascular system. This review discusses the contribution of purinergic P2Y receptors to endothelial dysfunction (ED) in numerous cardiovascular diseases (CVDs). Endothelial dysfunction can be defined as a shift from a "calm" or non-activated state, characterized by low permeability, anti-thrombotic, and anti-inflammatory properties, to a "activated" state, characterized by vasoconstriction and increased permeability, pro-thrombotic, and pro-inflammatory properties. This state of ED is observed in many diseases, including atherosclerosis, diabetes, hypertension, metabolic syndrome, sepsis, and pulmonary hypertension. Herein, we review the recent advances in P2Y receptor physiology and emphasize some of their unique signaling features in pulmonary endothelial cells.
Asunto(s)
Enfermedades Cardiovasculares/metabolismo , Células Endoteliales/metabolismo , Endotelio/metabolismo , Neovascularización Patológica/metabolismo , Receptores Purinérgicos P2Y/metabolismo , Transducción de Señal/fisiología , Animales , Endotelio/patología , Humanos , Inflamación/metabolismo , Inflamación/fisiopatología , Estrés Oxidativo/fisiología , Receptores Purinérgicos P2Y/fisiologíaRESUMEN
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. There are eight mammalian P2Y receptor subtypes divided into two subgroups (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and (P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain. The antagonism of P2Y12 receptors is used in pharmacotherapy for the prevention and therapy of cardiovascular events. The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation. The P2Y2 receptor agonist diquafosol is used for the treatment of the dry eye syndrome. The P2Y receptor subtypes differ in their amino acid sequences, their pharmacological profiles and their signaling transduction pathways. Recently, selective receptor ligands have been developed for all subtypes. The published crystal structures of the human P2Y1 and P2Y12 receptors as well as receptor models will facilitate the development of novel drugs for pharmacotherapy.
Asunto(s)
Receptores Purinérgicos P2Y/metabolismo , Receptores Purinérgicos P2Y/fisiología , Nucleótidos de Adenina/metabolismo , Animales , Humanos , Agregación Plaquetaria , Receptores Acoplados a Proteínas G/metabolismo , Receptores Acoplados a Proteínas G/fisiología , Receptores Purinérgicos P2Y/ultraestructura , Transducción de Señal , Relación Estructura-Actividad , Nucleótidos de Uracilo/metabolismoRESUMEN
The role of extracellular nucleotides and nucleosides as signaling molecules in cell-to-cell communication has now been clearly established. This is particularly true in the central and peripheral nervous system, where purines and pyrimidines are involved in both physiological and pathological interactions between neurons and surrounding glial cells. It can be thus foreseen that the purinergic system could represent a new potential target for the development of effective analgesics, also through the normalization of neuronal functions and the inhibition of glial cell activation. Research in the last 15 years has progressively confirmed this hypothesis, but no purinergic-based analgesics have reach the market so far; in the present review we have collected the more recent discoveries on the role of G protein-coupled P2Y nucleotide and of adenosine receptors expressed by both neurons and glial cells under painful conditions, and we have highlighted some of the challenges that must be faced to translate basic and preclinical studies to clinics.
Asunto(s)
Adenosina/metabolismo , Dolor/metabolismo , Receptores Purinérgicos P2Y/metabolismo , Adenosina Trifosfato/metabolismo , Analgésicos/farmacología , Animales , Sistema Nervioso Central/metabolismo , Humanos , Neuroglía/metabolismo , Neuronas/efectos de los fármacos , Dolor/patología , Receptores Purinérgicos/metabolismo , Receptores Purinérgicos P2Y/fisiología , Transducción de Señal/efectos de los fármacosRESUMEN
Nucleotides can contribute to the survival of different glial and neuronal models at the nervous system via activation of purinergic P2X and P2Y receptors. Their activation counteracts different proapoptotic events, such as excitotoxicity, mitochondrial impairment, oxidative stress and DNA damage, which concur to elicit cell loss in different processes of neurodegeneration and brain injury. Thus, it is frequent to find that different neuroprotective mediators converge in the activation of the same intracellular survival pathways to protect cells from death. The present review focuses on the role of P2Y1 and P2Y13 metabotropic receptors, and P2X7 ionotropic receptors to regulate the balance between survival and apoptosis. In particular, we analyze the intracellular pathways involved in the signaling of these nucleotide receptors to elicit survival, including calcium/PLC, PI3K/Akt/GSK3, MAPK cascades, and the expression of antioxidant and antiapoptotic genes. This review emphasizes the novel contribution of nucleotide receptors to maintain cell homeostasis through the regulation of MAP kinases and phosphatases. Unraveling the different roles found for nucleotide receptors in different models and cellular contexts may be crucial to delineate future therapeutic applications based on targeting nucleotide receptors for neuroprotection.
Asunto(s)
Receptores Purinérgicos P2X7/metabolismo , Receptores Purinérgicos P2Y1/metabolismo , Receptores Purinérgicos P2/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Encéfalo/metabolismo , Lesiones Encefálicas/metabolismo , Glucógeno Sintasa Quinasa 3/metabolismo , Humanos , Sistema de Señalización de MAP Quinasas , Neuroglía/metabolismo , Neuronas/metabolismo , Neuroprotección/fisiología , Fármacos Neuroprotectores/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Receptores Purinérgicos P2/fisiología , Receptores Purinérgicos P2X/metabolismo , Receptores Purinérgicos P2X/fisiología , Receptores Purinérgicos P2X7/fisiología , Receptores Purinérgicos P2Y/metabolismo , Receptores Purinérgicos P2Y/fisiología , Receptores Purinérgicos P2Y1/fisiología , Transducción de SeñalRESUMEN
G protein-coupled receptors (GPCRs) are the largest family of integral membrane receptors with 800 members in humans that are expressed at the cell surface responding to a large panel of extracellular stimuli. Recent advances indicate that GPCRs are also expressed in intracellular compartments where they fulfil important functions. Here, we will report on the mitochondrial localization and function of GPCRs.
Asunto(s)
Mitocondrias/fisiología , Receptores Acoplados a Proteínas G/fisiología , Animales , Membrana Celular/metabolismo , Humanos , Mitocondrias/metabolismo , Receptores de Angiotensina/fisiología , Receptores de Cannabinoides/fisiología , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Melatonina/fisiología , Receptores Purinérgicos P2Y/fisiología , Transducción de Señal/fisiologíaRESUMEN
KEY POINTS: Hydrocortisone (HC) is required for activation of large-conductance Ca2+ -activated K+ current (BK) by purinergic receptor agonists. HC reduces insertion of the stress-regulated exon (STREX) in the KCNMA1 gene, permitting protein kinase C (PKC)-dependent channel activation. Overlapping and unique purinergic signalling regions exist at the apical border of differentiated surface cells. BK channels localize in the cilia of surface cells. ABSTRACT: In the present study we investigated the role of hydrocortisone (HC) on uridine-5'-triphosphate (UTP)-stimulated ion transport in differentiated, pseudostratified epithelia derived from normal human bronchial basal cells. The presence of a UTP-stimulated, paxilline-sensitive large-conductance Ca2+ -activated K+ (BK) current was demonstrated in control epithelia but was not stimulated in epithelia differentiated in the absence of HC (HC0). Addition of the BK channel opener NS11021 directly activated channels in control epithelia; however, under HC0 conditions, activation only occurred when UTP was added after NS11021. The PKC inhibitors GF109203x and Gö6983 blocked BK activation by UTP in control epithelia, suggesting that PKC-mediated phosphorylation plays a permissive role in purinoceptor-stimulated BK activation. Moreover, HC0 epithelia expressed significantly more KCNMA1 containing the stress-regulated exon (STREX), a splice-variant of the α-subunit that displays altered channel regulation by phosphorylation, compared to control epithelia. Furthermore, BK channels as well as purinergic receptors were shown to localize in unique and overlapping domains at the apical membrane of ciliated surface cells. These results establish a previously unrecognized role for glucocorticoids in regulation of BK channels in airway epithelial cells.
Asunto(s)
Bronquios/fisiología , Células Epiteliales/efectos de los fármacos , Hidrocortisona/farmacología , Canales de Potasio de Gran Conductancia Activados por el Calcio/fisiología , Agonistas del Receptor Purinérgico P2Y/farmacología , Mucosa Respiratoria/fisiología , Adenosina Trifosfato/farmacología , Diferenciación Celular , Línea Celular , Células Epiteliales/fisiología , Humanos , Indoles/farmacología , Maleimidas/farmacología , Bloqueadores de los Canales de Potasio/farmacología , Proteína Quinasa C/fisiología , Inhibidores de Proteínas Quinasas/farmacología , Receptores Purinérgicos P2Y/fisiología , Mucosa Respiratoria/citología , Uridina Trifosfato/farmacologíaRESUMEN
During ischemia, numerous effective endogenous extracellular mediators have been identified, particularly, nucleosides such as adenosine as well as purinergic and pyrimidinergic nucleotides. They may play important regulatory roles within the cardiovascular system and notably as cardio-protectants. Indeed, the distribution of the P2Y receptors in mammalian heart includes several cellular constituents relevant for the pathophysiology of myocardial ischemia. Beside the well-known cardioprotective effect of adenosine, the additional protective role of P2Y receptors has emerged. However, interpretation of experimental results may be sometimes perplexing. This is due to the variability of: the experimental models, the endpoints criteria, the chemical structure of agonist and antagonist ligands and their concentrations, the sequences of drug administration with respect to the model used (before and/or during and/or after ischemia). The net effect may be in the opposite direction after a transient or a prolonged stimulation. Nevertheless, the overall reading of published data highlights the beneficial role of the P2Y2/4 receptor stimulation, the useful and synergistic role of P2Y6/11 receptor activation and even of the P2Y11 receptor alone in cardioprotection. More, the P2Y11 receptor could be involved in counter-regulation of profibrotic processes. Paradoxically, transient P2X7 receptor stimulation could contribute to the net cardioprotective effect of ATP. Recently, experimental data have shown that blocking the P2Y12 receptor after ischemia confers cardioprotection independently of platelet antiaggregatory effect. This suggests for P2Y receptors an important role in primary prevention and as a therapeutic target in myocardial protection during ischemia and reperfusion.
Asunto(s)
Daño por Reperfusión Miocárdica/prevención & control , Receptores Purinérgicos P2Y/fisiología , Calcio/metabolismo , Humanos , Receptores Purinérgicos P2/fisiología , Transducción de Señal , Uridina Trifosfato/fisiologíaRESUMEN
Purinergic signaling is important for many biological processes in humans. Purinoceptors P2Y are widely distributed in human digestive system and different subtypes of P2Y receptors mediate different physiological functions from metabolism, proliferation, differentiation to apoptosis etc. The P2Y receptors are essential in many gastrointestinal functions and also involve in the occurrence of some digestive diseases. Since different subtypes of P2Y receptors are present on the same cell of digestive organs, varying subtypes of P2Y receptors may have opposite or synergetic functions on the same cell. Recently, growing lines of evidence strongly suggest the involvement of P2Y receptors in the pathogenesis of several digestive diseases. In this review, we will focus on their important roles in the development of digestive inflammation and cancer. We anticipate that as the special subtypes of P2Y receptors are studied in depth, specific modulators for them will have good potentials to become promising new drugs to treat human digestive diseases in the near future.
Asunto(s)
Apoptosis , Proliferación Celular , Neoplasias del Sistema Digestivo/fisiopatología , Inflamación/fisiopatología , Receptores Purinérgicos P2Y/fisiología , Animales , Neoplasias del Sistema Digestivo/metabolismo , Neoplasias del Sistema Digestivo/patología , Progresión de la Enfermedad , Humanos , Inflamación/metabolismo , Inflamación/patología , Modelos Biológicos , Isoformas de Proteínas/metabolismo , Isoformas de Proteínas/fisiología , Receptores Purinérgicos P2Y/clasificación , Receptores Purinérgicos P2Y/metabolismoRESUMEN
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). P2Y receptors are widely expressed and play important roles in physiology and pathophysiology. One important example is the ADP-induced platelet aggregation mediated by P2Y1 and P2Y12 receptors. Active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel as well as the nucleoside analogue ticagrelor block P2Y12 receptors and thereby platelet aggregation. These drugs are used for the prevention and therapy of cardiovascular events. Moreover, P2Y receptors play important roles in the nervous system. Adenine nucleotides modulate neuronal activity and neuronal fibre outgrowth by activation of P2Y1 receptors and control migration of microglia by P2Y12 receptors. UDP stimulates microglial phagocytosis through activation of P2Y6 receptors. There is evidence for a role for P2Y2 receptors in Alzheimer's disease pathology. The P2Y receptor subtypes are highly diverse in both their amino acid sequences and their pharmacological profiles. Selective receptor ligands have been developed for the pharmacological characterization of the receptor subtypes. The recently published three-dimensional crystal structures of the human P2Y1 and P2Y12 receptors will facilitate the development of therapeutic agents that selectively target P2Y receptors. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.
Asunto(s)
Agonistas del Receptor Purinérgico P2Y/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Purinérgicos P2Y/química , Receptores Purinérgicos P2Y/fisiología , Adenosina Difosfato/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Encéfalo/metabolismo , Enfermedades Cardiovasculares/metabolismo , Humanos , Microglía/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Neuronas/metabolismo , Agregación Plaquetaria , Receptores Purinérgicos P2Y/metabolismo , Uridina Trifosfato/metabolismoRESUMEN
The mammalian nervous system is a complex, functional network of neurons, consisting of local and long-range connections. Neuronal growth is highly coordinated by a variety of extracellular and intracellular signaling molecules. Purines turned out to be an essential component of these processes. Here, we review the current knowledge about the involvement of purinergic signaling in the regulation of neuronal development. We particularly focus on its role in neuritogenesis: the formation and extension of neurites. In the course of maturation mammals generally lose their ability to regenerate the central nervous system (CNS) e.g. after traumatic brain injury; although, spontaneous regeneration still occurs in the peripheral nervous system (PNS). Thus, it is crucial to translate the knowledge about CNS development and PNS regeneration into novel approaches to enable neurons of the mature CNS to regenerate. In this context we give a general overview of growth-inhibitory and growth-stimulatory factors and mechanisms involved in neurite growth. With regard to neuronal growth, astrocytes are an important cell population. They provide structural and metabolic support to neurons and actively participate in brain signaling. Astrocytes respond to injury with beneficial or detrimental reactions with regard to axonal growth. In this review we present the current knowledge of purines in these glial functions. Moreover, we discuss organotypic brain slice co-cultures as a model which retains neuron-glia interactions, and further presents at once a model for CNS development and regeneration. In summary, the purinergic system is a pivotal factor in neuronal development and in the response to injury. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.
Asunto(s)
Astrocitos/fisiología , Sistema Nervioso Central/crecimiento & desarrollo , Regeneración Nerviosa , Neuritas/fisiología , Sistema Nervioso Periférico/crecimiento & desarrollo , Purinas/metabolismo , Animales , Astrocitos/metabolismo , Lesiones Traumáticas del Encéfalo/metabolismo , Sistema Nervioso Central/metabolismo , Gliosis/metabolismo , Humanos , Neuritas/metabolismo , Sistema Nervioso Periférico/metabolismo , Receptores Purinérgicos P2X/metabolismo , Receptores Purinérgicos P2X/fisiología , Receptores Purinérgicos P2Y/metabolismo , Receptores Purinérgicos P2Y/fisiologíaRESUMEN
The contractile and diastolic function of smooth muscle cells (SMCs) is closely related to penile erection and erectile dysfunction (ED). In addition to nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S), sulfur dioxide (SO2), estrogen receptor (ER), P2Y receptor, perivascular tissue (PVT), and calcium activated potassium channel (Kca) are found to be involved in the relaxation of SMCs. This review updates the mechanisms of the relaxation of SMCs and its relationship with ED.
Asunto(s)
Disfunción Eréctil/etiología , Miocitos del Músculo Liso/fisiología , Erección Peniana/fisiología , Monóxido de Carbono/fisiología , Disfunción Eréctil/fisiopatología , Humanos , Sulfuro de Hidrógeno/metabolismo , Masculino , Contracción Muscular , Músculo Liso , Óxido Nítrico/fisiología , Canales de Potasio Calcio-Activados/fisiología , Receptores de Estrógenos/fisiología , Receptores Purinérgicos P2Y/fisiología , Dióxido de Azufre/metabolismoRESUMEN
Bone development and homeostasis require the interplay between several cell types, including mesenchymal osteoblasts and osteocytes, as well as hematopoietic osteoclasts. Recent evidence suggests that cell proliferation, differentiation and apoptosis of both mesenchymal and hematopoietic stem cells, which are fundamental for tissue regeneration and treatment of degenerative diseases, are controlled by P2 receptors (i.e., P2X and P2Y receptors). Both types of P2 receptors are versatile transducers of diverse signals activated by extracellular nucleotides like ATP that are released in response to tissue injury, infection or shear stress. The P2X family of receptors has been shown to mediate multiple signaling events including the influx of calcium, activation of mitogen activated protein kinases (MAPKs) and induction of AP-1 family members known to regulate bone development. Support for the significance of P2X7 in regulating bone development and homeostasis has been provided by several studies focusing on animal models and single nucleotide polymorphisms. P2 receptors are functionally expressed in both bone forming osteoblasts and bone resorbing osteoclasts, while recent findings also suggest that these receptors translate mechanical stimuli in osteocytes. Their ability to respond to external nucleotide analogs renders these cell surface proteins excellent targets for skeletal regenerative therapies. This overview summarizes mechanisms by which nucleotide receptors control skeletal cells and contribute to bone tissue development remodeling and repair.
Asunto(s)
Desarrollo Óseo , Células Madre Hematopoyéticas/fisiología , Células Madre Mesenquimatosas/fisiología , Receptores Purinérgicos P2X/fisiología , Receptores Purinérgicos P2Y/fisiología , Animales , Humanos , Osteoblastos/metabolismo , Osteoclastos/metabolismo , Osteogénesis , Transducción de SeñalRESUMEN
Enhancement of insulin secretion is a major therapeutic approach for type 2 diabetes (T2D). Activation of P2Y purinergic receptor (P2YR) causes potentiation of insulin secretion in a glucose-dependent manner, making it a promising therapeutic target for T2D. Here we show that activation of P2YR to potentiate insulin secretion is mediated by adenylyl cyclase/cyclic AMP (cAMP) and the downstream effector, exchange protein directly activated by cAMP (Epac), leading to inhibition of voltage-dependent potassium (Kv) channels. P2YR-mediated Kv channel inhibition results in prolongation of action potential duration, and in turn elevates intracellular Ca(2+) level and insulin secretion. Taken together, the data indicate that cAMP/Epac/Kv channel pathway mediates P2YR-regulated insulin secretion, which may have important therapeutic implications for T2D.
Asunto(s)
AMP Cíclico/metabolismo , Factores de Intercambio de Guanina Nucleótido/metabolismo , Insulina/metabolismo , Canales de Potasio/metabolismo , Receptores Purinérgicos P2Y/fisiología , Animales , Calcio/metabolismo , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Masculino , Técnicas de Placa-Clamp , Ratas , Ratas Sprague-Dawley , Transducción de SeñalRESUMEN
OBJECTIVE: To investigate the relationship between ATP and IL-6 in mechanical stress-induced REX-1 expression in SHEDs. METHODS: Cells were stimulated with mechanical stress (0-2.5 gcm(-2)), IL-6 (0.1-5 ng/ml), or ATP (10-100 µM) for 2h in serum-free media. IL-6 and REX-1 expression was examined by qualitative and quantitative polymerase chain reaction. ATP release was measured using a bioluminescence assay. The molecular mechanisms of the signalling pathways were investigated using chemical inhibitors. RESULTS: Mechanical stress induced IL-6 and REX-1 mRNA expression and ATP release. JAK inhibitor I inhibited the increase in REX-1 expression and ATP release but not IL-6 induction. Furthermore, suramin inhibited the upregulation of REX-1 mRNA expression but not ATP release. Exogenous IL-6 promoted both ATP release and REX-1 expression. The IL-6-induced REX-1 expression was attenuated by a P2Y1-specific receptor antagonist. Moreover, REX-1 expression was upregulated in a dose-dependent manner by the addition of ATP or a P2Y1 agonist. This inductive effect was abolished by the P2Y1-specific receptor antagonist. CONCLUSIONS: ATP-P2Y1 signalling is involved in IL-6-regulated stress-induced REX-1 expression in SHEDs. These results imply the participation of mechanical stress, IL-6, and ATP in regulating the expression of REX-1, a pluripotent stem cell marker.
Asunto(s)
Adenosina Trifosfato/fisiología , Interleucina-6/fisiología , Factores de Transcripción de Tipo Kruppel/metabolismo , Receptores Purinérgicos P2Y/fisiología , Diente Primario/citología , Fenómenos Biomecánicos , Humanos , Mediciones Luminiscentes , Mecanotransducción Celular/fisiología , Células Madre Mesenquimatosas/fisiología , Agonistas del Receptor Purinérgico P2Y/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Purinérgicos P2Y/efectos de los fármacos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Estrés Mecánico , Regulación hacia ArribaRESUMEN
Acid-sensing pathways, which trigger mucosal defense mechanisms in response to luminal acid, involve the rapid afferent-mediated "capsaicin pathway" and the sustained "prostaglandin (PG) pathway." Luminal acid quickly increases protective PG synthesis and release from epithelia, although the mechanism by which luminal acid induces PG synthesis is still mostly unknown. Acid exposure augments purinergic ATP-P2Y signaling by inhibition of intestinal alkaline phosphatase activity. Since P2Y activation increases intracellular Ca2+, we further hypothesized that ATP-P2Y signals increase the generation of H2O2 derived from dual oxidase, a member of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family activated by Ca2+. Our recent studies suggest that acid exposure increases H2O2 output, followed by phospholipase A2 and cyclooxygenase activation, increasing PG synthesis. Released prostaglandin E2 augments protective HCO3- and mucus secretion via EP4 receptor activation. Thus, the PG pathway as a component of duodenal acid sensing consists of acid-related intestinal alkaline phosphatase inhibition, ATP-P2Y signals, dual oxidase 2-derived H2O2 production, phospholipase A2 activation, prostaglandin E2 synthesis, and EP4 receptor activation. The PG pathway is also involved in luminal bacterial sensing in the duodenum via activation of pattern recognition receptors, including Toll-like receptors and nucleotide-binding oligomerization domain 2. The presence of acute mucosal responses to luminal bacteria suggests that the duodenum is important for host defenses and may reduce bacterial loading to the hindgut using H2O2, complementing gastric acidity and anti-bacterial bile acids.
Asunto(s)
Dinoprostona/metabolismo , Duodeno/fisiología , Ácido Gástrico/fisiología , Mucosa Intestinal/fisiología , Transducción de Señal/fisiología , Adenosina Trifosfato/fisiología , Adhesión Bacteriana , Bicarbonatos/metabolismo , Calcio/metabolismo , Duodeno/metabolismo , Humanos , Peróxido de Hidrógeno , Concentración de Iones de Hidrógeno , Mucosa Intestinal/metabolismo , NADPH Oxidasas/metabolismo , Fosfolipasas A2/metabolismo , Prostaglandina-Endoperóxido Sintasas/metabolismo , Receptores de Reconocimiento de Patrones/fisiología , Subtipo EP4 de Receptores de Prostaglandina E/metabolismo , Receptores Purinérgicos P2Y/fisiologíaRESUMEN
To determine the involvement of purinergic receptors in coronary endothelium-dependent relaxation, the response to acetylcholine (1 × 10(-8) to 3 × 10(-7)M) was recorded in isolated rat hearts perfused according to the Langendorff procedure before and after 30 min of ischemia and 15 min of reperfusion and after the inhibition of nitric oxide synthesis with L-NAME (10(-4)M), in the absence and presence of the antagonist of purinergic P2X receptors, PPADS (3 × 10(-6)M), and of the antagonist of purinergic P2Y receptors, Reactive Blue 2 (3 × 10(-7)M). In control conditions, the relaxation to acetylcholine was not altered by PPADS or Reactive Blue 2. The relaxation to acetylcholine was reduced after ischemia-reperfusion, and, in this condition, it was further reduced by treatment with PPADS or Reactive Blue 2. Likewise, the relaxation to acetylcholine was reduced by L-NAME, and reduced further by Reactive Blue 2 but not by PPADS. These results suggest that the relaxation to acetylcholine may be partly mediated by purinergic receptors after ischemia-reperfusion, due to the reduction of nitric oxide release in this condition.
Asunto(s)
Acetilcolina/farmacología , Circulación Coronaria/efectos de los fármacos , Corazón/fisiología , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Receptores Purinérgicos P2X/fisiología , Receptores Purinérgicos P2Y/fisiología , Animales , Circulación Coronaria/fisiología , Inhibidores Enzimáticos/farmacología , Corazón/efectos de los fármacos , Masculino , Daño por Reperfusión Miocárdica/fisiopatología , NG-Nitroarginina Metil Éster/farmacología , Nitroprusiato/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Antagonistas del Receptor Purinérgico P2X/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Fosfato de Piridoxal/análogos & derivados , Fosfato de Piridoxal/farmacología , Ratas Sprague-Dawley , Triazinas/farmacología , Vasodilatación/efectos de los fármacos , Vasodilatación/fisiología , Vasodilatadores/farmacologíaRESUMEN
Colocalization of purinergic P2X and P2Y receptors in dorsal root ganglion sensory neurons implies that these receptors play an integrative role in the nociceptive transmission process under inflammatory conditions. In the present study, behavioural and in vivo electrophysiological methods were used to examine the peripheral role of P2 receptors in the persistent nociceptive responses induced by subcutaneous bee venom injection (2 mg/mL) in. Sprague-Dawley rats Local pretreatment with the wide-spectrum P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS; 1 mmol/L, 50 µL) 10 min prior to s.c. bee venom injection significantly suppressed the duration of spontaneous nociceptive lifting/licking behaviour, inhibited mechanical hyperalgesia and decreased the firing of spinal dorsal horn wide dynamic range neurons in response to bee venom, without affecting primary thermal and mirror-image hyperalgesia. The localized antinociceptive action of PPADS was not due to a systemic effect, because application of the same dose of PPADS to the contralateral side was not effective. The results suggest that activation of peripheral P2 receptors is involved in the induction of nociceptive responses, mechanical hyperalgesia and the excitation of sensory spinal neurons.
Asunto(s)
Venenos de Abeja/farmacología , Conducta Animal/efectos de los fármacos , Dolor Nociceptivo/fisiopatología , Receptores Purinérgicos P2X/fisiología , Receptores Purinérgicos P2Y/fisiología , Células Receptoras Sensoriales/efectos de los fármacos , Potenciales de Acción/efectos de los fármacos , Animales , Conducta Animal/fisiología , Ganglios Espinales/efectos de los fármacos , Ganglios Espinales/metabolismo , Masculino , Dolor Nociceptivo/inducido químicamente , Dolor Nociceptivo/metabolismo , Dimensión del Dolor , Umbral del Dolor/efectos de los fármacos , Antagonistas del Receptor Purinérgico P2X/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Ratas Sprague-Dawley , Receptores Purinérgicos P2X/metabolismo , Receptores Purinérgicos P2Y/metabolismo , Células Receptoras Sensoriales/metabolismoRESUMEN
UDP sugars were identified as extracellular signaling molecules, assigning a new function to these compounds in addition to their well defined role in intracellular substrate metabolism and storage. Previously regarded as an orphan receptor, the G protein-coupled receptor P2Y14 (GPR105) was found to bind extracellular UDP and UDP sugars. Little is known about the physiological functions of this G protein-coupled receptor. To study its physiological role, we used a gene-deficient mouse strain expressing the bacterial LacZ reporter gene to monitor the physiological expression pattern of P2Y14. We found that P2Y14 is mainly expressed in pancreas and salivary glands and in subpopulations of smooth muscle cells of the gastrointestinal tract, blood vessels, lung, and uterus. Among other phenotypical differences, knock-out mice showed a significantly impaired glucose tolerance following oral and intraperitoneal glucose application. An unchanged insulin tolerance suggested altered pancreatic islet function. Transcriptome analysis of pancreatic islets showed that P2Y14 deficiency significantly changed expression of components involved in insulin secretion. Insulin secretion tests revealed a reduced insulin release from P2Y14-deficient islets, highlighting P2Y14 as a new modulator of proper insulin secretion.
Asunto(s)
Insulina/metabolismo , Músculo Liso/fisiología , Receptores Purinérgicos P2Y/fisiología , Animales , Secuencia de Bases , Cartilla de ADN , Femenino , Vaciamiento Gástrico , Intolerancia a la Glucosa , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Ratones , Ratones Noqueados , Reacción en Cadena de la Polimerasa , Receptores Purinérgicos P2Y/genéticaRESUMEN
Resident macrophages in the liver (Kupffer cells) produce various cytokines and chemokines, and have important roles in hepatitis and liver fibrosis. The cells are activated by various factors, for example lipopolysaccharide (LPS), which is an endotoxin and is high in the blood of patients with liver cirrhosis. Involvement of P2 receptors in the release of pro-inflammatory cytokines from Kupffer cells is little. In this study, we investigated purinergic signaling in the release of pro-inflammatory cytokines, such as IL-6 and TNF-α, from liver Kupffer cells of C57BL/6 mice (KUP5 cells). KUP5cells were isolated from C57BL/6 mice and cultivated with Dulbecco's modified Eagle's medium. The cells were stimulated with LPS. LPS-induced IL-6 production by KUP5 cells was suppressed significantly by pretreatments with non-selective P2 antagonist suramin, P2Y13antagonist MRS2211, and ecto-nucleotidase, whereas P2Y receptor agonists, significantly increased the IL-6 production. P2Y13knockdown reduced LPS-induced IL-6 production, but by less than 50%. These results would suggest that P2Y receptors including P2Y13and others, may involves in LPS-induced IL-6 production in Kupffer cells, leading to the liver inflammation. Therefore, we first showed the importance of purinergic signaling via P2Y receptors in the activation of Kupffer cells and liver injury, which is worthwhile in drug development for liver diseases.